MedPath

Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury

Phase 4
Conditions
Neoplasms
Liver Injury
Interventions
Registration Number
NCT01802996
Lead Sponsor
Cttq
Brief Summary

This purpose of this study is to evaluate the evaluate the efficacy of Magnesium Isoglycyrrhizinate Injection in the prevention of antineoplastic chemotherapy related acute liver injury.

Detailed Description

Total subjects: 2040, experimental group of 1360 patients, control group of 680 patients. According to the study subjects receiving antineoplastic chemotherapy, subjects are stratified randomize.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
2040
Inclusion Criteria
  1. Male or female aged 18-75 years;
  2. Patients with malignant tumor accord with chemotherapy indication, candidate to a chemotherapy treatment, disease is not restricted;
  3. Accorded with the following chemotherapy plan: included cis-platinum, ≥60mg/m2/course; included oxaliplatin, ≥85mg/m2/course; included cyclophosphamide, ≥600mg/m2/course; included gemcitabine, ≥60mg/m2/course;
  4. ECOG≤2;
  5. Estimates survival time≥3 months;
  6. TBIL≤1.0×ULN, ALT、AST≤1.0×ULN; blood examination, uronoscopy, stool examination, renal function tests and electrocardiogram are normal;
  7. Patients have been apart from the previous chemotherapy to finish above 2 weeks (including 2 weeks).
Exclusion Criteria
  1. Patients with partial liver radiotherapy;
  2. Hepatitis B or C virus replication in the state, the patient will need antiviral therapy;
  3. Patients have serious heart diseases, liver kidney diseases, or metabolism function disorder;
  4. Patients combined with cellular immune therapy;
  5. Within 2 weeks of application or currently possible applications of drugs(polyene phosphatidylcholine, reduced glutathione, tiopronin and other hepatoprotective and choleretic drugs), interference with the study;
  6. Pregnancy, or patients during breast feeding;
  7. Patients have known hypersensitivity to Glycyrrhizin;
  8. Patients are participating, or have participated in other Clinical studies of new drugs within 4 weeks.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm IMagnesium Isoglycyrrhizinate InjectionMagnesium Isoglycyrrhizinate Injection 200mg IV on days 1-5
Primary Outcome Measures
NameTimeMethod
The incidence of liver injury0-15 days

anyone of ALT、AST、ALP、TBIL、DBIL、γ-GT\>ULN

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (27)

The first hospital of Nanjing

🇨🇳

Nanjing, Jiangsu, China

The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

🇨🇳

Hefei, Anhui, China

China PLA General Hospital

🇨🇳

Beijing, Beijing, China

Fujian Province-owned Hospital

🇨🇳

Fuzhou, Fujian, China

Fuzhou General Hospital of Nanjing Military Area Command

🇨🇳

Fuzhou, Fujian, China

The First Affiliated Hospital of Guangzhou Medical College

🇨🇳

Guangzhou, Guangdong, China

The Affiliated Tumor Hospital of Guangxi Medical University

🇨🇳

Nanning, Guangxi, China

The First Affiliated Hospital of Guangxi Medical University

🇨🇳

Nanning, Guangxi, China

The first hospital of Hebei Medical University

🇨🇳

Shijiazhuang, Hebei, China

The people's Hospital of Wuhan University

🇨🇳

Wuhan, Hubei, China

Changzhou Second People's Hospital

🇨🇳

Changzhou, Jiangsu, China

The First Affiliated Hospital of Nanchang University

🇨🇳

Nanchang, Jiangxi, China

The 81st hospital of PLA

🇨🇳

Nanjing, Jiangsu, China

The Second Affiliated Hospital of Nanjing Medical University

🇨🇳

Nanjing, Jiangsu, China

The First Affiliated Hospital of General Hospital of PLA ( 304 )

🇨🇳

Beijing, Beijing, China

Guangdong General Hospital

🇨🇳

Guangzhou, Guangdong, China

The second hospital of Hebei Medical University

🇨🇳

Shijiazhuang, Hebei, China

The First Affiliated Hospital of Zhengzhou University

🇨🇳

Zhengzhou, Henan, China

Tumour Hospital Affiliated to Guangzhou Medical College

🇨🇳

Guangzhou, Guangdong, China

Xiangya Hospital of Central South University

🇨🇳

Changsha, Hunan, China

Wuxi Fourth People's Hospital

🇨🇳

Wuxi, Jiangsu, China

Nanjing General Hospital of Nanjing Military Area Command

🇨🇳

Nanjing, Jiangsu, China

The First Affiliated Hospital of Nanjing Medical University

🇨🇳

Nanjing, Jiangsu, China

Wuxi People's Hospital

🇨🇳

Wuxi, Jiangsu, China

Affiliated Hospital of Xuzhou Medical College

🇨🇳

Xuzhou, Jiangsu, China

Affiliated Hospital of Medical College of Qiingdao University

🇨🇳

Qingdao, Shandong, China

The First Affiliated Hospital of Xinjiang Medical University

🇨🇳

Wulumuqi, Xinjiang, China

© Copyright 2025. All Rights Reserved by MedPath